NXTCNextCure, Inc.

$36M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$18M

Net Income

-$18M

EPS (Diluted)

$-7.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$206M

Total Liabilities

$8M

Stockholders' Equity

$198M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$18M	-$18M	-1.0%
Net Income	-$18M	-$18M	+0.4%

NXTC Q2 2022 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena